John A. Herrmann III - Dec 14, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: EVP, Chief Legal Officer
Signature: /s/ Mark Casey, Attorney-in-Fact
Stock symbol: NVAX
Transactions as of: Dec 14, 2023
Transactions value $: -$3,983
Form type: 4
Date filed: 12/18/2023, 05:09 PM
Previous filing: Jun 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise		+2.1K	+17.75%		13.9K	Dec 14, 2023	Direct	F1
transaction	NVAX	Common Stock	Tax liability	-$3.98K	-700	-5.02%	$5.69	13.2K	Dec 14, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Restricted Stock Units	Options Exercise	$0	-2.1K	-100%	$0.00^*	0	Dec 14, 2023	Common Stock	2.1K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax common stock.
F2	The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3	The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.